{"name":"Candel Therapeutics, Inc.","slug":"candel-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AdV-tk","genericName":"AdV-tk","slug":"adv-tk","indication":"Metastatic pancreatic cancer","status":"phase_3"},{"name":"CAN-2409","genericName":"CAN-2409","slug":"can-2409","indication":"Metastatic solid tumors","status":"phase_2"},{"name":"Placebo + valacyclovir","genericName":"Placebo + valacyclovir","slug":"placebo-valacyclovir","indication":"Likely oncolytic virus-based immunotherapy in combination with valacyclovir (specific indication unknown without trial details)","status":"phase_3"},{"name":"aglatimagene besadenovec + valacyclovir","genericName":"aglatimagene besadenovec + valacyclovir","slug":"aglatimagene-besadenovec-valacyclovir","indication":"Metastatic pancreatic cancer","status":"phase_3"}]}],"pipeline":[{"name":"AdV-tk","genericName":"AdV-tk","slug":"adv-tk","phase":"phase_3","mechanism":"AdV-tk is an oncolytic adenovirus expressing herpes simplex virus thymidine kinase that replicates in tumor cells and sensitizes them to ganciclovir, triggering both direct viral lysis and immune activation.","indications":["Metastatic pancreatic cancer","Ovarian cancer"],"catalyst":""},{"name":"CAN-2409","genericName":"CAN-2409","slug":"can-2409","phase":"phase_2","mechanism":"CAN-2409 is a T-cell engager that targets the CD3 component of the T-cell receptor.","indications":["Metastatic solid tumors"],"catalyst":""},{"name":"Placebo + valacyclovir","genericName":"Placebo + valacyclovir","slug":"placebo-valacyclovir","phase":"phase_3","mechanism":"Valacyclovir is an antiviral prodrug that inhibits herpes simplex virus DNA polymerase, while the placebo control allows assessment of the combination's efficacy in a phase 3 trial.","indications":["Likely oncolytic virus-based immunotherapy in combination with valacyclovir (specific indication unknown without trial details)"],"catalyst":""},{"name":"aglatimagene besadenovec + valacyclovir","genericName":"aglatimagene besadenovec + valacyclovir","slug":"aglatimagene-besadenovec-valacyclovir","phase":"phase_3","mechanism":"Aglatimagene besadenovec is an oncolytic adenovirus expressing IL-12 that replicates in tumor cells and triggers immune activation, combined with valacyclovir (an antiviral) to modulate viral replication kinetics.","indications":["Metastatic pancreatic cancer","Ovarian cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQY0EyRFZ3NjVXbWN2Mzh2aDNJZS1GR3pmR3d4VHd1MUxMVElCb21LYjdUQjctZUcyQ1NJY1BKWldKVkpnZVRVMVhHZVRhUVViZHAyejBtMnRxSlFlV0xfaGdhVC0wd2huQi13Tk5uUGpjWGFkX1pHNGVHWDF2UnFQdUdmVF9WSHowcVlab1ZJbUxvSFBKcWc?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Glioma Pipeline Expands as 180+ Pharma Companies Advance - openPR.com","headline":"Glioma Pipeline Expands as 180+ Pharma Companies Advance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxQOGdNMTN1RElfTmhkU0xLTTZlV3Z4OTNEUjFyYjJLNzVjaFdUbDVHSjFrUXREZjAyLXF5clh4Q2x4U29Eb2loQkttODdYOVlUd2hFZkxPOEJDV0xIdEQ1OGZEaUQxMHVCR09NLS1Cd19QS0JxX3M5Q1I2RGtHQUpxTlZ2ZGpvUTNJdVo5ejQ5MGktaC1fdE85MnliWVc5eHpwdnZyMXhQU1d5N01MX3ItZktMLTd0bW5fcTVxNDVOeU44YnFSd3FjVWt6LXhhcXRadnAtRGlNYTR4MmlQbkNaY01fZTJLek1vWXdfRzZxV1FKSVNXV0RwbThRR21NNUlwbFExSG9CVnhuLVhiZFlkWHYwYXdJQzR3SGZSQzl6MS1HRjVZOTNKTTVzdm1RTmRwRVc0MWdrMTVMa2RQRTFaSlZncFNKVGJBYS1ibzdBNHI?oc=5","date":"2026-03-19","type":"pipeline","source":"Barchart.com","summary":"Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics - Bar","headline":"Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQS2VKS21XU2tnTkRPRFNiQ3R0aE1kR1U4RllzZE5uOVFwWW1yY2xEaHB6UUkzMUdGQmlQRVk4dVlWeTN0ZnFnak5hd2hPc3liTUNhak5XTWFqN1NNUjFwTm1FYU9OS3Z3TGFyQzV1bTFqZGVOUlhyU2QyM3VaNkhhRmN1T2ZiNjNXNWNPZmdvNzZhTFE3M1hpUi1MWlMtMVJ6NGdZNUJralFqOFg4d1hlanBpTTM?oc=5","date":"2026-02-20","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNS05IbnFMNEVHSTdxNkd5aXk1OU5aNU1uM2FDQ0daY29EcGdPdUlDZGhPLTFrNmxIRzl6RF9IcGc0TElQMFg0ZE9XN05GQTNCVjd3NjdTeHRmd2lPelBhdnNnQ1JZdjEyWlNCTzBfQUNMNEJWN1ZwRzFWaWVhejNXRVBZWWZfMThZbzlPU3V2ZTFaVFFPQm40bHJ4TktzUmR4ajRjWmt4TktEWVRVdGlFNlF4Y2hiWGVaaTVuakJSbnp0Ry1jN3A2UTRBWDdENGtueGFUSmpxUUg1Z0pkSGJaUmJNUmJBZXM?oc=5","date":"2026-02-11","type":"trial","source":"proactiveinvestors.com","summary":"Candel Therapeutics to highlight glioblastoma immunotherapy data at Boston summit | NASDAQ:CADL - proactiveinvestors.com","headline":"Candel Therapeutics to highlight glioblastoma immunotherapy data at Boston summit | NASDAQ:CADL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxOQTR0d1l3a3B2VmdFdjY0QkJVZ01rYmtPV0gtNERtMXMyN1lXdTdpOTFRRjFjREFaSENvbDByU2JUdzRVZ2Mxc3dsbU8zYm5MUElhVGl3RHkyU3NzaTZ5b3U2T1NOUGlUaE90MDNtUTB1Z2xIeWRSZ1NfTEpwU1hzcDZiZnpYX0puU1lTZmYyMDZ6YS02YnowdU1jbU1wZmh0d3pYNmpiYV9VVnpzTXRva09wdE9RUzZ1d3dWOGtVMGJwVmFaVkJndlJMM09oSWRhUWZKVUJJSW1iSXBWc0p5bm83ZlZOYmxaZXdEOG1ZZHZib2pxcUltWmFrdjJha0JhRFNKYTF3QlFjd0hEN29VTVJB?oc=5","date":"2026-02-04","type":"trial","source":"PR Newswire","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - PR Newswire","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-17","type":"pipeline","source":"simplywall.st","summary":"Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - simplywall.st","headline":"Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxQX1pEOTJvZzZKa1g5X0kxendaN2lNVHpBZzFmSGpuOWZKS01BVUlrYVViWVV5cGRJZHNUc29hNnFqQWg4REptbno1X054ZlQxUjFZaWZ6X2ROdnJ0TUNsUTNfLXBWV0NWeDZnSXlqNDBLTzFuQjA1MVVvXzNiMTVoWWNJQTVRb3NISF9BUHlDS1dzN3JhTmVITVFUcEhIVUtPaUtjMU1jUHZkTU8wUXpUZTF2c0c5MkdoNWdXMTEwZXBKQXZXRTViZ2dHaDZYbFlTbktOcUlTOFU3QlJvOWh1QVhUT29uZXlreWNOZlZmbXNsOXBlVFdNWFhJY2R6VWoxeEtN?oc=5","date":"2025-12-11","type":"pipeline","source":"Benzinga","summary":"Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On - Benzinga","headline":"Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPQ1l6WDVhS09LRkFaSXhOUWZEaGUxdkFZVDdsRl9QLXlXOWZSRUtoRkpvTmtweV8wRklDYlRFSlNkNWlLNUVzRXJhdl9LX3lSS2FCcjJmNmFTNkhGekt1Tk40RmVWSlM0cURjTl94c3dpSzFVNXgxd0xsN1RnWE9qQkdNZ2kyVnhVSVhYOEdBOXNXUEJp?oc=5","date":"2025-10-15","type":"pipeline","source":"Pharmaceutical Executive","summary":"Roundup: Capital Flows into Pharma with Funding Rounds and Loan Facilities - Pharmaceutical Executive","headline":"Roundup: Capital Flows into Pharma with Funding Rounds and Loan Facilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxNYW5QcjZuank0VHBxTVhSQlpwd25YUlJSck5rdVlTR01naXJSWEFjcmFNODBKMjB4eFBZWWZjNWhHTHl3aTNvcUhpZUtINUhxVnBtR2ZaM0lNdEVQUGF6TVpJS19nYlJHOVdQdV9CM19oaEdOMS1mQndFOVZCQVNLb0lZYWNKd1haYklEa3B1TlAxN3k1c250X3hxeUxCeVJBN0FKdjdHUFF5cFZYRUtONTJDNGg3UUo5NGR5YnlTOUZhd0lZdUZ0UlE2RW9LOXR0eHlveFlRMExkVGVoTC1NbnNKTm5VZFV3ZVpWa0R0eFhJZlIzMURWTUZnSzF2MmNmOVZrR3VXQ2Ewb0xJSkw5WXExZldxcWxzbWZOS3otUVYxQ3dnMFg1LQ?oc=5","date":"2025-10-14","type":"pipeline","source":"PR Newswire","summary":"Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer - PR Newswire","headline":"Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Imm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQam5ZdzFUTXk5OGMzN2lJZ19mT19Eb0RGNWM3cEp1MWtTLS1sNWZMb0xYbDJfUE5ibzE4SERpYUZvd1MySUdnWWRtQjl6bURYSGM5LTlfdjIyWmJlNHVyMGZWOXVmZE5sVlJRVmFmQzBCdUxjaXBzOWhLWGk2TnVzanoyaEhSeVpHX2VwZ3IxQmpxRmtBVWdoLTd2bi1tcS1qYnhPMmdkSUpTYTBBMFVJaQ?oc=5","date":"2025-10-13","type":"regulatory","source":"seekingalpha.com","summary":"Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - seekingalpha.com","headline":"Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNUUVwYUNIMHQ5SjljcmFwV0dOYmM4TUJXRHNUajQ3SVA1Q0hZVjF1M0lJSlE5d0hNaFdoNHlDSUhKZFF1cmxkaGFaMlNQdXdjeEY2eHAtTTluU3h4RDZOTUw3UUd0ajQ2YzFiOU85VGRVcWFTTHNFcmowWjZmMmtQVnBlbkpTekNEMDExMzg1RnExNU9IVjZybjNzMkRFZVp1YzM2YUxHT2tScUNjVEVnSGxSTHpQZXJLUjEyUTVkQ2loQUVfYUVoellzMWdVQi1pUU5Ka1AtSzAzOXJCZFRVSEJKTzhoZ09yMzJ6U2tYSTh6REp5WHpRNFRpMmt6QQ?oc=5","date":"2025-05-27","type":"trial","source":"Proactive financial news","summary":"Candel Therapeutics to host June 3 call on positive Phase 3 results for prostate cancer therapy - Proactive financial news","headline":"Candel Therapeutics to host June 3 call on positive Phase 3 results for prostate cancer therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPUG5OYzhNWk0wdUFyT29uUW1hX3JuMUVZaU0wc3JUYlBNRGFKR1ZZTW8tM1BaeUtLOUlrV1pQSFpzVlRTbWVyY0o4RDdKRHpmcmpNeEV0QXpFeUNadUl0WDJvOEoxMEpWUENhTm02YjFpTVNMSXJrUXpfOFFpOHh2WXBoM3RFTGVRay14RUh3b1pzN2RUdk9OOGhmWUsyV2tjNWhYblFTcw?oc=5","date":"2025-01-09","type":"pipeline","source":"Pharma Voice","summary":"After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win - Pharma Voice","headline":"After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}